Project Grant R41TR005758
Award Date 8/15/25
Completion Date 8/14/26
Dollars Obligated $350K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
GRANDVIEW, OH 43212, USA
Similar Awards
- This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $304,951 to Neucore Bio, Inc. is focused on developing a scalable, cost-effective manufacturing process for extracellular vesicle (EV)-based gene therapy delivery systems targeting peripheral nervous system disorders. The research aims to optimize methods for EV isolation, purification, and cargo loading to improve therapeutic efficacy. Key objectives include establishing...
- This federal Project Grant award from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286), supports the development of extracellular vesicles (EVs) as therapeutic carriers. The $622,000 award, effective August 1, 2024 through July 31, 2027, will enable researchers at The Washington University in St. Louis to engineer endothelial cell-derived EVs to efficiently...
- This Project Grant award of $349,909.00 from the National Center for Advancing Translational Sciences (NCATS, CFDA 93.350) will support the development of Nanoengineering Corporation's viral vector sizing tool to improve gene therapy analytics and reduce drug development costs. The funding will enable the commercialization of Nanoengineering's proprietary electrospray differential mobility analysis (ES-DMA) method, which can quickly and accurately measure the size of virus capsids at an...
- The National Center for Advancing Translational Sciences (NCATS), through its CFDA 93.350 Federal Grant Program, awarded a $294,541 Project Grant to Cellular Vehicles Inc. on June 1, 2024. The purpose of this award is to develop an automated system for producing and delivering cell-laden hydrogel therapies. The project aims to create a novel, standardized process for formulating, encapsulating, and directly injecting cell-laden hydrogels into diseased tissues. This is intended to improve the...
- This Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) provides $3,878,453.00 to DTX Pharma Inc., a for-profit biotechnology company, to develop an RNA therapeutic for the treatment of Charcot Marie Tooth 1A, a neurological disorder. The award period runs from June 15, 2023 to December 14, 2025. Through this funding, DTX Pharma will leverage its expertise in RNA therapeutics to advance the development of a siRNA-based treatment...
- This Cooperative Agreement award from the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310) provides $452,378 to the University of Florida to evaluate and optimize a high-throughput platform for loading genome editing payloads into extracellular vesicles (EVs). The project aims to develop scalable GMP manufacturing procedures for EV-based genome editing products, establish critical quality attributes, and evaluate the pharmacology and toxicology of...
- This Project Grant award from the National Center for Advancing Translational Sciences (NCATS), CFDA 93.350, provides $313,372.00 to D4Z4 Medicine, Inc. to develop a long-read sequencing-based molecular diagnostic assay for Facioscapulohumeral Muscular Dystrophy (FSHD). The project aims to standardize and validate the long-read sequencing assay, increase its capacity by adding target regions, and optimize a bioinformatics pipeline with a user-friendly interface for analyzing the sequencing data....
- This $419,398 Project Grant award, funded by the National Center for Advancing Translational Sciences (NCATS) CFDA Program 93.350, is supporting research to accelerate the development and delivery of oligonucleotide therapeutics (ONTs). The project aims to address the key barrier of biological membrane permeability that limits the ability of large, charged ONT molecules to reach their therapeutic targets within cells. The research at the University of California, Irvine will explore novel...
- This $2,696,128 federal Project Grant award, funded under the Department of Defense's Military Medical Research and Development program (CFDA 12.420), supports preclinical development of a gene replacement therapy using novel adeno-associated virus (AAV) vectors to treat familial cerebral cavernous malformations (CCM). The prime awardee is Duke University, which is collaborating with the University of Chicago as a sub-awardee. Duke's work focuses on developing the gene therapy treatment, while...
- This federal Project Grant award for $390,000.00 from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859) supports the development of new tools for high-throughput characterization of extracellular RNA, DNA, and vesicles in bodily fluids. The primary objectives are to: 1) develop methods to reliably control for technical variability, RNA degradation, and complexity in cell-free RNA (cfRNA) analysis, including...